pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

5,811 catalysts · 5,811 phase readout · 2,343 8k filing · 426 earnings · 3 pdufa · 2 approval · 1 adcom

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-03: 0 catalysts2026-08-04: 0 catalysts2026-08-05: 0 catalysts2026-08-06: 0 catalysts2026-08-07: 0 catalysts2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 14 catalysts2026-08-11: 16 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 11 catalysts2026-10-29: 20 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: grant×type: filing×type: phase readout×clear all
type
  • phase readout5,811
  • 8k filing2,343
  • earnings426
  • pdufa3
  • approval2
  • adcom1
therapy area

no tagged catalysts yet

Date TBD

11
›COMPLETEDphase readoutNCT04346238: Characterization of the Interruptions of the GAA Expansion and Study of Their Influence on the Severity of Friedreich's Ataxia

Sponsor: University Hospital, Montpellier. Phase: . Conditions: Friedreich Ataxia

full page →ctgov ↗
›RECRUITINGphase readoutNCT07570758: A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.

Sponsor: ERX Pharmaceuticals. Phase: PHASE2. Conditions: Obesity & Overweight

full page →ctgov ↗
›SUSPENDEDphase readoutNCT06586658: Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal Cells

Sponsor: Shanghai Changzheng Hospital. Phase: EARLY_PHASE1. Conditions: Renal Cell Carcinoma

full page →ctgov ↗
›COMPLETEDphase readoutNCT03651648: Apnea Treatment in Premature Infants Using an Automatic Vibro-tactile Stimulator Triggered by the Detection of Apnea-bradycardia.

Sponsor: Rennes University Hospital. Phase: NA. Conditions: Apnea of Prematurity

full page →ctgov ↗
›RECRUITINGphase readoutNCT06428448: Study to Evaluate the REMEDY SPECTRUM GV IM Spacer Nail in the Treatment of Ankle-Related Infections

Sponsor: OsteoRemedies, LLC. Phase: PHASE2. Conditions: Periprosthetic Joint Infection

full page →ctgov ↗
›RECRUITINGphase readoutNCT07105449: THC Titration of High-Potency Cannabis Concentrates

Sponsor: Centre for Addiction and Mental Health. Phase: NA. Conditions: THC

full page →ctgov ↗
›RECRUITINGphase readoutNCT06212349: Therapeutic-educational Physiotherapy on Pain, Physical-functionality and Quality of Life in Women With Endometriosis.

Sponsor: University of Valencia. Phase: NA. Conditions: Endometriosis, Chronic Pain, Women's Health

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07676526: Association Between Chronic Kidney Disease Stage and Circulating FGF23 Cleavage Intensity in Patients With Chronic Kidney Disease

Sponsor: Centre Hospitalier Universitaire de Saint Etienne. Phase: NA. Conditions: CKD - Chronic Kidney Disease

full page →ctgov ↗
›RECRUITINGphase readoutNCT07615478: Effect of Hot Spring Therapy on Central Fatigue Elimination During Altitude Training

Sponsor: Macao Polytechnic University. Phase: NA. Conditions: Central Fatigue, Altitude Training, Cognitive Impairment, Hydrotherapy, Balneotherapy, Sports Performance

full page →ctgov ↗
›RECRUITINGphase readoutNCT07677878: Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL

Sponsor: Liping Dou. Phase: PHASE1. Conditions: ALL (Acute B-Lymphoblastic Leukemia)

full page →ctgov ↗
›RECRUITINGphase readoutNCT06983743: A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

Sponsor: Erasca, Inc.. Phase: PHASE1. Conditions: Metastatic Solid Tumors

full page →ctgov ↗
← prev
page 117 of 117
next →